Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077750 | 0.95 | MEN1 (0.53) | VEGFAEGLN1GPR119HRH3CHRM2 | |
| SCHEMBL2236220 | 0.89 | VEGFA (0.54) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL2363123 | 0.89 | VEGFA (0.56) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL2858333 | 0.89 | TP53 (0.58) | VEGFAEGLN1GPR119HRH3CHRM2 | |
| SCHEMBL18608789 | 0.89 | MEN1 (0.58) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL4156092 | 0.89 | VEGFA (0.58) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL5536182 | 0.89 | VEGFA (0.68) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL23250104 | 0.87 | VEGFA (0.55) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL21198803 | 0.87 | VEGFA (0.55) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL20910175 | 0.87 | VEGFA (0.55) | VEGFAEGLN1GPR119HRH3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4722203-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024251080-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2024-12-12 | — | — | WO | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-113521299-B | Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| CN-1310911-C | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-18 | — | — | CN | disclosed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | VEGFA 4663/4885EGLN1 1276/4885GPR119 2426/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VEGFA 4663/4885EGLN1 1276/4885GPR119 2426/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VEGFA 4663/4885EGLN1 1276/4885GPR119 2426/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | VEGFA 1155/4885EGLN1 2880/4885GPR119 2232/4885 |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | VEGFA 3068/4885EGLN1 524/4885GPR119 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.